These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19782419)

  • 21. Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
    Lee J; Park YH; Kim WS; Lee SS; Ryoo BY; Yang SH; Park KW; Kang JH; Park JO; Lee SH; Kim K; Jung CW; Park YS; Im YH; Kang WK; Lee MH; Ko YH; Ahn YC; Park K
    Eur J Cancer; 2005 Jul; 41(10):1402-8. PubMed ID: 15963893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
    Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
    Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma.
    Liu QF; Wang WH; Wang SL; Liu YP; Huang WT; Lu N; Zhou LQ; Ouyang H; Jin J; Li YX
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):806-13. PubMed ID: 24495590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
    Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
    Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents.
    Wang ZY; Li YX; Wang WH; Jin J; Wang H; Song YW; Liu QF; Wang SL; Liu YP; Qi SN; Fang H; Liu XF; Yu ZH
    Blood; 2009 Nov; 114(23):4771-6. PubMed ID: 19812381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma.
    Wu RY; Li YX; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Fang H; Ren H; Liu QF; Wang ZY; Qi SN; Lu NN; Chen B; Zhang XM; Zhou LQ; Liu XF; Yu ZH
    Am J Clin Oncol; 2014 Feb; 37(1):41-6. PubMed ID: 22992625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
    Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
    J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
    Yong W; Zheng W; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemotherapy and radiotherapy for non-Hodgkin's lymphomas of the nasal cavity].
    Nie DH; Hu WH; Gao YH; Wu Y; Zhang SP
    Zhonghua Zhong Liu Za Zhi; 2004 May; 26(5):312-4. PubMed ID: 15312373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
    Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
    Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.
    Economopoulos T; Psyrri A; Dimopoulos MA; Kalogera-Fountzila A; Pavlidis N; Tsatalas C; Nikolaides C; Mellou S; Xiros N; Fountzilas G
    Cancer J; 2007; 13(5):327-34. PubMed ID: 17921732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
    Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
    Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic analysis of 62 cases of nasal NK/T-cell lymphoma].
    Xiao J; Wang SS; Huang Y; Chen LK; Guan ZZ; Huang HQ; Xia ZJ; Xu RH; Lin TY
    Ai Zheng; 2006 Sep; 25(9):1173-7. PubMed ID: 16965665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E;
    Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.